medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2016, Número 3

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2016; 14 (3)


Anticoagulantes orales y su implicación en la cirugía dermatológica

Guerra VÁE, Marfil RLJ, Ocampo CJ

Idioma: Español
Referencias bibliográficas: 27
Paginas: 222-227
Archivo PDF: 125.27 Kb.


RESUMEN

Entre 25 y 38% de los pacientes que se someten a un procedimiento cutáneo usan agentes antitrombóticos, por lo que el dermatólogo debe conocer bien su farmacodinamia y farmacocinética, sus indicaciones, así como los posibles efectos adversos. La decisión de mantener o suspender el tratamiento con anticoagulantes orales radica en el riesgo de hemorragia frente a la posibilidad de que se provoque un evento trombótico cuando éstos se suspendan. En este artículo hacemos una revisión de la aspirina y los anticoagulantes orales y sus implicaciones en la cirugía cutánea.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Callahan S, Goldsberry A, Kim G, Yoo S. The management of antithrombotic medication in skin surgery. Dermatol Surg 2012; 38: 1417-26.

  2. Dixon AJ, Dixon MP, Dixon JB. Bleeding complications in skin cancer surgery are associated with warfarin but not aspirin therapy. Br J Surg 2007; 94: 1356-60.

  3. Otley CC. Continuation of medically necessary aspirin and warfarin during cutaneous surgery. Mayo Clin Proc 2003; 78: 1392-6.

  4. Kovich O, Otley CC. Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. J Am Acad Dermatol 2003; 48: 233-7.

  5. Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol 2006; 62(5): 509-11.

  6. Ansell J, Hirsh J, Poller L et al. The pharmacology and management of the vitamin K antagonists: the Seventh accp Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204-33.

  7. García D, Ageno W, Bussey H et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 1: prevention. Am J Hematol 2009; 84: 579-83.

  8. Lewis KG, Dufresne RG. A meta-analysis of complications attributed to anticoagulation among patients following cutaneous surgery. Dermatol Surg 2008; 34: 160-4.

  9. Child N, Anjum N, Keohane SG, Cooper HL. A guide to anticoagulation and endocarditis prophylaxis during cutaneous surgery. Clin Exp Dermatol 2010; 35(8): 817-22.

  10. Juurlink DN. Drug interactions with warfarin: what clinicians need to know. cmaj 2007; 177(4): 369-71.

  11. Syed S, Adams BB, Liao W et al. A prospective assessment of bleeding and international normalized ratio in warfarin-anticoagulated patients having cutaneous surgery. J Am Acad Dermatol 2004; 51: 955-7.

  12. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.

  13. Gonsalves WI, Pruthi RK, Patnaik MM. The new oral anticoagulants in clinical practice. Mayo Clin Proc 2013; 88(5): 495-511.

  14. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Engl J Med 2009; 361(24): 2342-52.

  15. Bordeaux JS, Martires KJ, Goldberg D et al. Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications. J Am Acad Dermatol 2011; 65: 576-83.

  16. Patel MR, Mahaffey KW, Garg J et al. rocket af Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.

  17. Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358(26): 2765-75.

  18. Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358(26): 2776-86.

  19. Turpie AGG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (record-4): a randomised trial. Lancet 2009; 373(9676): 1673-80.

  20. Lassen MR, Raskob GE, Gallus A et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361(6): 594-604.

  21. Lassen MR, Raskob GE, Gallus A et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (advance-2): a randomised double-blind trial. Lancet 2010; 375(9717): 807-15.

  22. Lassen MR, Gallus A, Raskob GE et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363(26): 2487-98.

  23. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364(9): 806-17.

  24. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92.

  25. Weisman S, Graham D. Evaluation of the benefits and risks of lowdose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162: 2197-202.

  26. Bartlett GR. Does aspirin affect outcome of minor cutaneous surgery? Br J Plast Surg 2001; 54: 214-6.

  27. Lawrence C, Sakuntabhai A, Tiling-Grosse S. Effect of aspirin and nonsteroidal anti-inflammatory drug therapy on bleeding complications in dermatological surgery patients. J Am Acad Dermatol 1994; 31: 988-92.




2020     |     www.medigraphic.com